GlassScriptPhysician profile
Tara Lee Smith
NPI 1821575002
$1,874.39
in general payments reported to CMS, 2019-2025
19 companies · $714 in 2025
The $714 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.58 · 2022: $13.91 · 2023: $479 · 2024: $652 · 2025: $714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,844.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $327.75 | 2023-2025 | |
| Axsome Therapeutics, INC. | $300.86 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $243.94 | 2023-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $174.53 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Indivior INC. | $125.81 | 2022-2025 | Sublocade |
| Novo Nordisk INC | $120.57 | 2023 | Wegovy |
| Gilead Sciences, INC. | $104.70 | 2023 | Epclusa |
| Vanda Pharmaceuticals INC. | $93.65 | 2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $80.16 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.31 | 2024-2025 | Caplyta |
| Merz North America, INC. | $40.31 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $37.53 | 2025 | Uzedy |
| Lundbeck LLC | $37.36 | 2025 | Rexulti |
| Neurocrine Biosciences, INC. | $30.24 | 2025 | |
| Pharmacosmos Therapeutics INC. | $20.06 | 2024 | Monoferric |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $16.78 | 2025 | Qelbree |
| Braeburn INC. | $15.70 | 2025 | Brixadi |
| Echosens North America, INC. | $15.58 | 2021 | |
| Almatica Pharma LLC | $13.55 | 2024 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.